Novel antibiotics: Are we still in the pre–post-antibiotic era?

PURPOSE: Therapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gra...

Descripción completa

Detalles Bibliográficos
Autores principales: Draenert, R., Seybold, U., Grützner, E., Bogner, J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382537/
https://www.ncbi.nlm.nih.gov/pubmed/25701222
http://dx.doi.org/10.1007/s15010-015-0749-y
_version_ 1782364598480928768
author Draenert, R.
Seybold, U.
Grützner, E.
Bogner, J. R.
author_facet Draenert, R.
Seybold, U.
Grützner, E.
Bogner, J. R.
author_sort Draenert, R.
collection PubMed
description PURPOSE: Therapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gram-negative organisms, new antibiotics are urgently needed. METHODS: This paper provides a review of novel antibiotic compounds which are already in clinical development, mainly in phase III clinical trials. CONCLUSION: Each of these new trials increases the possibility of new antibiotics receiving approval.
format Online
Article
Text
id pubmed-4382537
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-43825372015-04-07 Novel antibiotics: Are we still in the pre–post-antibiotic era? Draenert, R. Seybold, U. Grützner, E. Bogner, J. R. Infection Review PURPOSE: Therapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gram-negative organisms, new antibiotics are urgently needed. METHODS: This paper provides a review of novel antibiotic compounds which are already in clinical development, mainly in phase III clinical trials. CONCLUSION: Each of these new trials increases the possibility of new antibiotics receiving approval. Springer Berlin Heidelberg 2015-02-21 2015 /pmc/articles/PMC4382537/ /pubmed/25701222 http://dx.doi.org/10.1007/s15010-015-0749-y Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Review
Draenert, R.
Seybold, U.
Grützner, E.
Bogner, J. R.
Novel antibiotics: Are we still in the pre–post-antibiotic era?
title Novel antibiotics: Are we still in the pre–post-antibiotic era?
title_full Novel antibiotics: Are we still in the pre–post-antibiotic era?
title_fullStr Novel antibiotics: Are we still in the pre–post-antibiotic era?
title_full_unstemmed Novel antibiotics: Are we still in the pre–post-antibiotic era?
title_short Novel antibiotics: Are we still in the pre–post-antibiotic era?
title_sort novel antibiotics: are we still in the pre–post-antibiotic era?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382537/
https://www.ncbi.nlm.nih.gov/pubmed/25701222
http://dx.doi.org/10.1007/s15010-015-0749-y
work_keys_str_mv AT draenertr novelantibioticsarewestillintheprepostantibioticera
AT seyboldu novelantibioticsarewestillintheprepostantibioticera
AT grutznere novelantibioticsarewestillintheprepostantibioticera
AT bognerjr novelantibioticsarewestillintheprepostantibioticera

Ejemplares similares